Work

Complete Remissions In 3 of 12 Patients with Pediatric Acute Lymphoblastic Leukemia (ALL) During Phase I Testing of the Anti-CD22 Immunotoxin Moxetumomab Pasudotox

Year: 2010

Type: article

Source: Blood

DOI: 10.1182/blood.v116.21.3246.3246

Authors: Alan Wayne, Deepa Bhojwani, Kelly Richards, Maryalice Stetler-Stevenson, Lewis B. Silverman, Sima Jeha, Ching-Hon Pui, Jennifer McDevitt, David J. FitzGerald, Robert J. Kreitman, Robert J. Lechleider, Ira Pastan

Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research, St. Jude Children's Research Hospital, Boston Children's Hospital, Dana-Farber Cancer Institute, Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2559917387

FWCI: 1.197

Cites:

Cited by: 8

Related to: 10